Hemoteq's Fancy New Coat
Executive Summary
Hemoteq's hemocompatible coating for medical devices could help address one of the last remaining concerns about drug-eluting stents: the risk of subacute and late thrombosis. But for a small company to compete in drug-eluting stents isn't easy.
You may also be interested in...
TCT Highlights: Late Stent Thrombosis Controversy Continues
Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).
Boston Scientific Takes Conor to Court over DES
Boston Scientific has filed suite in the Netherlands to keep Conor Medsystems from selling its paclitaxel-coated stent in Europe. This is the latest effort by interventional cardiology companies to use litigation to protect market share.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.